The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen
The New York Times – Business:
This post first appeared in The New York Times – Business. Read the original article.
Written by
in